Rigel Pharmaceuticals, Inc.
RIGL
Positions held
Your positionsRIGL isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Rigel Pharmaceuticals operates in the biotechnology industry, which is known for its potential to deliver groundbreaking therapies and treatments, positioning the company for significant growth as it develops innovative
- In the latest quarter, Rigel reported a revenue increase of 34% compared to the prior quarter, reaching $79 million.
- The company's gross margin stood at 89.2%, demonstrating strong profitability despite previous fluctuations.
- The biotechnology sector is highly competitive, and Rigel faces challenges in maintaining its market position against larger, more established firms with greater resources.
- Rigel's revenue growth has been negative at -22.6% year-over-year, indicating potential struggles in scaling its operations.
- The company reported a net income loss of $25.1 million in 2023, highlighting ongoing financial challenges.
Fundamentals
| Market cap | $910.08M | Enterprise value | $854.70M | Trailing P/E | 2.89 | Forward P/E | 9.86 |
| PEG | — | Price / book | 2.14 | Beta | 1.19 | Dividend yield | 0.00% |
| Revenue growth | -22.6% | Earnings growth | -73.2% | Gross margin | 75.6% | Operating margin | 30.0% |
| Profit margin | 116.3% | ROE | 126.9% | ROA | 15.0% | Debt / equity | 0.09 |
| Current ratio | 1.94 | Free cash flow | -$31.76M | Analyst recommendation | none | Mean target | $63.00 |
| 52w high | $52.24 | 52w low | $24.95 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $78.7M | $58.8M | $69.8M | $69.5M | $102M |
| Op margin | 30.0% | 20.2% | 33.2% | 40.9% | 60.1% |
| Net income | $17.3M | $8.7M | $268M | $27.9M | $59.6M |
| Gross margin | 89.2% | 92.2% | 91.5% | 93.2% | 95.6% |
| Gross profit | $70.2M | $54.2M | $63.8M | $64.7M | $97.2M |
| Operating income | $23.6M | $11.9M | $23.2M | $28.4M | $61.1M |
- Revenue +34% vs prior quarter ($79M vs $59M).
- Gross margin 89.2% (was 92.2% prior quarter).
- Operating margin expanded to 30%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $294M | $179M | $117M | $120M | — |
| Op margin | 42.6% | 13.5% | -17.5% | -45.1% | — |
| Net income | $367M | $17.5M | -$25.1M | -$58.6M | — |
| Gross margin | 93.3% | 89.6% | 93.9% | 98.5% | — |
| Gross profit | $275M | $161M | $110M | $118M | — |
| Operating income | $125M | $24.2M | -$20.5M | -$54.2M | — |
Headlines — watch
• [WARN · fundamentals] Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates
News
2026-10-06 · Knight Therapeutics Announces Launch of TAVALISSE® in Brazil
2026-10-02 · Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2026-09-02 · Rigel to Participate in Upcoming September Investor Conferences
2026-08-16 · Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope
2026-08-14 · Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
2026-08-13 · Rigel Says Breast Cancer Drug Veppanu Now Available in US, Puerto Rico
2026-08-12 · Rigel (RIGL) Q2 2026 Earnings Call Transcript
2026-08-05 · Rigel Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
2026-08-05 · Rigel Pharmaceuticals Q2 Earnings Call Highlights
2026-08-04 · Arvinas, Inc. Q2 2026 Earnings Call Summary
Price (daily)
Full chart · RSI · MACD · patterns